Neoantigen-based peptide vaccine

Phase 2Vaccine

TThe First Affiliated Hospital of Nanchang University

Neoantigen-based peptide vaccine is one of 73 small molecule programs targeting Advanced Malignant Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Malignant Solid TumorsRecruiting

Second-Line TreatmentRecruiting

First-Line TreatmentRecruiting

Advanced Malignant Solid TumorsPreclinical

Recruiting

Second-Line TreatmentPhase 2

Recruiting

First-Line TreatmentPreclinical

Recruiting

Competition

Competitive Landscape

74 competitors in First-Line Treatment

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

4 2

Lexapro

AbbVie

Phase 3

1 3

Tuoyi

SSun Yat-sen University

Phase 3

6 4

Vepesid

AAvyxa

Phase 3

3 5

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

2 6

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 7

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 8

Wellbutrin

GGlaxo Dba Glaxosmithkline

Phase 3

1 9

Zoloft

VViatris Specialty LLC

Phase 3

1 10

Effexor

WWyeth-Lederle Vaccines

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/ARecruiting

Second-Line Treatment

NCT06751966

N/ARecruiting

First-Line Treatment

NCT06752044

N/ARecruiting

First-Line Treatment

NCT06751914

Clinical

Trials by Indication[1]

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Neoantigen-based peptide vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neoantigen-based peptide vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neoantigen-based peptide vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Nanchang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 2[1]
Company: TThe First Affiliated Hospital of Nanchang University

Neoantigen-based peptide vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Second-line Treatment2 trials

First-line Treatment2 trials

Advanced Malignant Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News